Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1823844rdf:typepubmed:Citationlld:pubmed
pubmed-article:1823844lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1823844lifeskim:mentionsumls-concept:C1533592lld:lifeskim
pubmed-article:1823844lifeskim:mentionsumls-concept:C0047506lld:lifeskim
pubmed-article:1823844pubmed:issue4lld:pubmed
pubmed-article:1823844pubmed:dateCreated1992-10-2lld:pubmed
pubmed-article:1823844pubmed:abstractTextThe bone metastases of a malignant, non-secreting paraganglioma were treated with [131I]metaiodobenzylguanidine (131I-MIBG) over a 10-year period. Initial treatment (131I-MIBG: 9.6 GBq) resulted in a decrease in the number of bone metastases from 16 to 2. At three years, a relapse with primary tumor regrowth and liver metastasis was again treated with 131I-MIBG (22.2 GBq). A decrease in the number of bone metastases and MIBG uptake was again observed.lld:pubmed
pubmed-article:1823844pubmed:languageenglld:pubmed
pubmed-article:1823844pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1823844pubmed:citationSubsetIMlld:pubmed
pubmed-article:1823844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1823844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1823844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1823844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1823844pubmed:statusMEDLINElld:pubmed
pubmed-article:1823844pubmed:issn0368-3249lld:pubmed
pubmed-article:1823844pubmed:authorpubmed-author:BesnardJ CJClld:pubmed
pubmed-article:1823844pubmed:authorpubmed-author:BaulieuJ LJLlld:pubmed
pubmed-article:1823844pubmed:authorpubmed-author:GuilloteauDDlld:pubmed
pubmed-article:1823844pubmed:authorpubmed-author:CalaisGGlld:pubmed
pubmed-article:1823844pubmed:authorpubmed-author:LeflochOOlld:pubmed
pubmed-article:1823844pubmed:issnTypePrintlld:pubmed
pubmed-article:1823844pubmed:volume35lld:pubmed
pubmed-article:1823844pubmed:ownerNLMlld:pubmed
pubmed-article:1823844pubmed:authorsCompleteYlld:pubmed
pubmed-article:1823844pubmed:pagination313-4lld:pubmed
pubmed-article:1823844pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:meshHeadingpubmed-meshheading:1823844-...lld:pubmed
pubmed-article:1823844pubmed:articleTitle[131I]metaiodobenzylguanidine treatment of a malignant paraganglioma.lld:pubmed
pubmed-article:1823844pubmed:affiliationService de Médecine Nucléaire, Hôpital Bretonneau, Tours, France.lld:pubmed
pubmed-article:1823844pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1823844pubmed:publicationTypeCase Reportslld:pubmed